MedTrace Logo

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00126685 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

therapeutic autologous dendritic cells

Sponsors & Collaborators

  • Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen

    lead OTHER

Principal Investigators

  • Gerold Schuler · Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00126685 on ClinicalTrials.gov